Application note: Characterising chemokine receptor inhibitors with Alpha SureFire Ultra assays
In this application note, PerkinElmer discuss how their ValiScreen CXCR2 GPCR cell line (#ES-145-C) was utilised to examine the downstream effects of chemokine receptor modulation using multiple blocking antibodies and a small molecule…
The ideal research platform for inhibitor development is able to screen for both large and small molecule inhibitors within the same assay format. Assays developed for the detection of small molecule inhibitors may not be amenable to detection of blocking antibodies. One way to overcome this is to utilise assays that probe the downstream signalling events that are impacted by both types of inhibitors. As such, it is important to have available simple, fast and sensitive assays for the measurement of antibody modulation of receptors in a cellular system.
The measurement of protein phosphorylation is a useful tool for measuring the modulation of receptor activation by both antibodies and small molecules. Alpha SureFire Ultra assays are mix-and-read assays that use the highly sensitive Alpha bead-based proximity detection system, coupled with CaptSure immobilisation technology, to assess relative levels of both phosphorylated and total states for a variety of proteins. These assays do not suffer from interference from exogenous antibodies. As there are no wash steps, these assays are automation friendly, may be applied to both small- and large-scale screens, and used to assess phosphorylation status in complex matrices including diverse cell culture models and serum samples.
To demonstrate the utility of Alpha SureFire Ultra assays for measuring a variety of inhibitors to different cell surface receptors, we chose to examine CXCR2 pathways in a cellular model system. Assay conditions were optimised to measure the blockage of this receptor (activated with appropriate agonists). Receptor activity modulation was assayed by the detection of ERK and AKT phosphorylation status using the Alpha SureFire Ultra assays.
This application note is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Related content from this organisation
- Application note: Simultaneous dual phosphoprotein target analysis with Alpha Terbium SureFire Ultra Multiplex
- Expert view: Toward physiological relevance in drug discovery and development
- Streamlining drug discovery assays for cancer and cardiovascular disease
- Case Study: Characterisation of hiPSCs by Phenotypic Screening
- Application Note: Alpha Terbium SureFire Ultra Multiplex: simultaneous dual phosphoprotein target analysis